Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
The high prevalence of metabolic disorders and early adoption of novel therapeutics contribute to the regional market dominance
Increased competition may eventually influence pricing and expand access to treatment
East Asia: In East Asia, China and Japan are experiencing strong demand for GLP-1 receptor agonists, driven by an increasing prevalence of type 2 diabetes and expanding access to diabetes treatments
Youre Not Alone
A muscle mass in a patient with polymyalgia rheumatica
2018, doi: 10.1007/s00296-018-4142-x Chourpiliadis, C., et al, "Use of Common Psychiatric Medications and Risk and Prognosis of Amyotrophic Lateral Sclerosis," JAMA Network Open, June 4, 2024, doi:10.1001/jamanetworkopen.2025.14437 Meron, M.K., et al, "GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes," Journal of Clinical Endocrinology & Metabolism, Feb.10, 2026, doi: 10.1210/clinem/dgag056 Luo, Y., et al, "GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential," BMC Ophthalmology, Jan
US$ 24.68
US$ 23.57
US$ 24.74
US$ 24.52
